Literature DB >> 22407703

Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure.

Takashi Onaka, Naoto Takahashi, Masatomo Miura, Akihito Yonezawa, Kazunori Imada, Kenichi Sawada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22407703     DOI： 10.1002/ajh.23125

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

2.  Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant.

Authors:  Takashi Onaka; Naoto Takahashi; Masatomo Miura; Akihito Yonezawa
Journal:  Clin Case Rep       Date:  2017-03-17

3.  The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.

Authors:  Yasuhiro Taniguchi; Naoto Takahashi; Masatomo Miura; Chikara Hirase; Sanae Sueda; Jorge Luis Espinoza; Shinya Rai; Shoko Nakayama; Kentaro Serizawa; Takahiro Kumode; Yosaku Watatani; Yasuyoshi Morita; Hirokazu Tanaka; Itaru Matsumura
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.